Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2021-01-19 Director's Dealing
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and the Korea Exchange. This is a standard regulatory filing used to disclose insider transactions (share acquisitions by an executive, Lee Tae Wha). In the provided classification schema, reports of personal share transactions by company directors and executives are categorized as 'Director's Dealing'.
2021-01-19 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings, and the purpose of holding shares by major shareholders and their special related parties (directors/executives). This corresponds to the 'Major Shareholding Notification' category.
2021-01-19 Korean
[기재정정]투자판단관련주요경영사항(제대혈 유래 줄기세포 아토피피부염 치료제 국내 독점판권/통상실시권 설정 및 기술전수 계약 체결)
Management Reports Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a previous 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details changes to a licensing and technology transfer agreement between Kangstem Biotech and Hyundai Bioland. Since it is a formal regulatory disclosure of a material business event that does not fit into specific categories like M&A or financial reports, it is classified as a Regulatory Filing (RNS).
2020-12-10 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory announcement of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2020-12-10 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '강스템바이오텍' covering the period from January 1, 2020, to September 30, 2020. It contains detailed financial data, business operations, capital structure, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special related parties (insiders). This type of filing is specifically used to notify the market of significant changes in shareholding percentages (crossing thresholds or changes in control). In the provided taxonomy, 'Major Shareholding Notification' (MRQ) is the correct category for this type of disclosure.
2020-11-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.